Sensei Biotherapeutics, Inc. Stock Price, News & Analysis

Sensei Biotherapeutics (Nasdaq: SNSE) reported Phase 1/2 dose-expansion results for solnerstotug at ESMO 2025 showing dose-dependent activity and tolerability in PD-(L)1 resistant “hot” tumors.

Key data: 6-month PFS 50% at 15 mg/kg in PD-(L)1 resistant patients versus overall 6-month PFS of 37% across prior PD-(L)1 progressors; six clinical responses occurred at 15 mg/kg including one durable complete response (MCC, 54+ weeks). Safety: six Grade 1 CRS events (all at 15 mg/kg) and no new safety signals (Phase 1 n=98, dose expansion n=64).

Sensei plans Phase 2 trials in 2L NSCLC and PD-(L)1 resistant MCC in 2026, subject to FDA feedback and financing. Investor webcast Oct 20, 2025 at 8:00 AM ET.

Sensei Biotherapeutics (NASDAQ:SNSE) announced a virtual Key Opinion Leader (KOL) event scheduled for October 20, 2025, at 8:00 AM ET. The event will feature Dr. Kyriakos Papadopoulos, Co-Director of Clinical Research at START San Antonio, who will discuss immunotherapy-resistant solid tumors.

The presentation will include updates on Phase 2 study plans and complete data from the Phase 1/2 dose expansion cohort for Solnerstotug (formerly SNS-101), their conditionally active monoclonal antibody targeting VISTA in PD-(L)1 resistant tumors. The data will also be presented at ESMO on October 17th.

Sensei Biotherapeutics (NASDAQ:SNSE), a clinical stage biotech company developing next-generation cancer therapeutics, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.

CEO John Celebi will conduct one-on-one investor meetings on September 8, 2025. The company's on-demand corporate presentation will be available starting September 5, 2025, at 7:00 a.m. ET. Investors can access the webcast replay in the Investors section of Sensei's website for approximately 90 days after the event.

Sensei Biotherapeutics (NASDAQ:SNSE) reported Q2 2025 financial results and provided updates on its clinical programs. The company's lead candidate solnerstotug showed promising results in its Phase 1/2 trial, demonstrating a favorable safety profile in combination with cemiplimab. The study included 64 patients in the dose expansion cohort, with 41 patients having prior PD-(L)1 resistance.

Financial highlights include cash position of $28.6 million as of June 30, 2025, expected to fund operations into Q2 2026. The company reported a reduced net loss of $4.9 million compared to $7.1 million in Q2 2024, with decreased R&D expenses of $2.5 million and G&A expenses of $2.7 million.

Full data from the Phase 1/2 dose expansion cohort is expected by year-end 2025, with upcoming presentation at ESMO Congress 2025 in October.

Sensei Biotherapeutics (NASDAQ: SNSE) has announced an upcoming presentation of clinical data at the ESMO Congress 2025 in Berlin, Germany. The presentation will focus on results from the Phase 1 dose expansion cohort studying solnerstotug, both as a monotherapy and in combination with Regeneron's PD-1 inhibitor Libtayo® (cemiplimab).

The study specifically examines patients with advanced solid tumors resistant to prior PD-(L)1 therapy. Dr. Kyriakos Papadopoulos from START, San Antonio will present the findings on October 17, 2025 during a mini oral session.

Sensei Biotherapeutics (NASDAQ: SNSE) has announced a 1-for-20 reverse stock split effective June 16, 2025, at 5:00 p.m. Eastern Time. The split aims to maintain Nasdaq Capital Market listing compliance by meeting minimum bid price requirements. Trading under the split-adjusted basis will begin on June 17, 2025, with a new CUSIP number 81728A207. The reverse split will reduce outstanding shares from 25.2 million to approximately 1.3 million, and authorized shares from 250 million to 12.5 million. The company will adjust conversion and exercise prices for outstanding stock options, RSUs, and warrants proportionally. Stockholders will receive cash payments for fractional shares, with Equiniti Trust Company serving as the exchange agent.

Sensei Biotherapeutics (NASDAQ: SNSE) reported Q1 2025 financial results and clinical progress for its cancer therapeutic solnerstotug. The company reported favorable clinical data in PD-(L)1 resistant patients, with response rates nearly three times higher than expected. The Phase 1/2 trial has completed enrollment with 63 total patients, including 10 MSS CRC patients in monotherapy and 53 in the cemiplimab combination arm. Financially, Sensei reported cash position of $34.3 million, with runway into Q2 2026. Q1 2025 showed reduced losses with net loss of $6.9 million compared to $8.0 million in Q1 2024. R&D expenses decreased to $3.7 million from $4.9 million year-over-year, while G&A expenses dropped to $3.5 million from $3.8 million.

Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage biotechnology company specializing in next-generation cancer therapeutics, has announced its participation in an upcoming industry event. John Celebi, President and CEO, will be a panelist in the New Radiotherapy and Targeted Therapy Approaches discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference. The panel is scheduled for Monday, April 7 at 2:00 p.m. ET.

Sensei Biotherapeutics (NASDAQ: SNSE) reported its full year 2024 financial results and clinical progress for solnerstotug, their conditionally active antibody targeting VISTA. Key clinical highlights include:

In the Phase 1/2 dose expansion study, among 21 evaluable PD-(L)1 resistant tumor patients, the combination therapy showed 14% overall response rate (3x higher than historical rates) and 62% disease control rate. The study achieved target enrollment of 60 patients, with full expansion data expected by year-end 2025.

Financial results show:

• Cash position: $41.3M as of December 31, 2024
• R&D expenses: $18.6M (vs $18.3M in 2023)
• G&A expenses: $13.0M (vs $18.8M in 2023)
• Net loss: $30.2M (vs $34.1M in 2023)

The company expects its current cash runway to extend into Q2 2026.